ANDEMBRY

This brand name is authorized in Estonia, France, Lithuania, UK.

Active ingredients

The drug ANDEMBRY contains one active pharmaceutical ingredient (API):

1	Garadacimab UNII 32W6AJL0DY - GARADACIMAB
	Garadacimab is a fully human IgG4/lambda recombinant monoclonal antibody which binds to the catalytic domain of activated Factor XII (FXIIa and βFXIIa) and inhibits its catalytic activity. The inhibition of FXIIa, the first factor activated in the contact system, prevents HAE attacks by blocking the activation of prekallikrein to kallikrein and the generation of bradykinin, which is associated with inflammation and swelling in HAE attacks.
	Read more about Garadacimab

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
ANDEMBRY Solution for injection	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
B06AC07		B Blood and blood forming organs → B06 Other hematological agents → B06A Other hematological agents → B06AC Drugs used in hereditary angioedema
Discover more medicines within B06AC07

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	3108518, 3108529, 3108596, 3108608
FR	Base de données publique des médicaments	63003892, 68937264
LT	Valstybinė vaistų kontrolės tarnyba	1102710, 1102711, 1102712, 1102713